"Gas station heroin": how a legal wellness supplement became a Schedule I drug — and what the millions already dependent do now

TL;DR

• On 1 July 2026, the US Drug Enforcement Administration filed a draft notice of intent to place 7-hydroxymitragynine (7-OH) and three related substances into Schedule I of the Controlled Substances Act — the same category as heroin and LSD. The temporary scheduling runs for two years with a potential one-year extension.
• 7-OH is a concentrated, semi-synthetic derivative of the kratom plant sold nationwide in gas stations, smoke shops, vape shops and convenience stores as gummies, tablets, drinks and capsules — often labelled as "wellness", "energy" or "mood support".
• HHS confirmed the compound has no accepted medical use and is highly addictive, with opioid-like effects on the mu-opioid receptor.
• Kratom itself is legal in most US states. 7-OH is a downstream product that concentrates the plant's most opioid-active metabolite to levels the plant does not naturally produce. This is the distinction the DEA is drawing.
• Withdrawal from 7-OH looks and feels like opioid withdrawal. On 7 July, telehealth provider Workit Health became the first major online clinic to launch a dedicated 7-OH treatment pathway. Standard opioid-use-disorder treatment — buprenorphine — appears effective.
• The regulatory action lands inside a global regulatory patchwork: Australia banned kratom in 2005, the UK in 2016 under the Psychoactive Substances Act, Thailand legalised it in 2021, and the EU regulates it country-by-country.
• What to do if you or someone you know uses these products: stop with a plan, not cold. Buprenorphine access, not moral pressure, is what closes the dependence loop.

What actually happened

On 1 July, the DEA filed a draft notice of intent in the Federal Register — published Monday 7 July — to temporarily place 7-hydroxymitragynine and three chemically related analogues into Schedule I of the Controlled Substances Act. The Department of Health and Human Services provided the eight-factor analysis that supports the move. The Food and Drug Administration had recommended the scheduling action earlier in the year.

The immediate legal effect is limited: temporary scheduling under the CSA lasts two years, with a possible one-year extension, and applies to products above a specified 7-OH concentration threshold. In practice this means the gummies, tablets and shots currently sold as "7-OH" or "7-hydroxy" products will disappear from retail shelves in the coming weeks. Products containing only naturally occurring kratom leaf remain legal at federal level, though 6 US states already ban kratom outright.

Two days later, on 3 July, [Newser/NYT] confirmed HHS's determination that 7-OH has no accepted medical use and a significant potential for abuse. On 7 July, Workit Health — an Ann Arbor-based online addiction clinic — announced a dedicated 7-OH treatment pathway, offering buprenorphine prescriptions, medical supervision and peer support to a patient population its Chief Medical Officer, Dr Justin Coffey, described as growing "faster than we've seen for any single compound since fentanyl analogues".

That last comparison matters. Hold onto it.

What 7-OH actually is (and why "it's just kratom" is wrong)

Kratom is Mitragyna speciosa, a tree native to Thailand, Malaysia and Indonesia. Its leaves contain more than 40 alkaloids. Two matter clinically: mitragynine, which makes up the bulk of the alkaloid content in the raw leaf, and 7-hydroxymitragynine, which occurs in trace quantities — typically less than 2% of total alkaloid content in whole-leaf material.

7-OH is a partial agonist at the mu-opioid receptor. Mitragynine also touches the mu receptor but with lower affinity and a mixed pharmacology. In the natural leaf, 7-OH's effects are heavily diluted by everything else in the plant.

The 7-OH products the DEA is scheduling are not leaf. They are concentrated extracts, semi-synthetic isolates and formulated tablets where 7-OH is the primary active ingredient at concentrations 10× to 50× higher than anything that occurs in nature. Some products contain 30–50 mg of isolated 7-OH per serving. For scale: a standard therapeutic dose of oral morphine in an opioid-naïve adult is 5–15 mg. The comparison is imperfect — 7-OH is a partial agonist and dose-response is not linear across opioids — but the general point survives the caveat.

This is the industry sleight of hand. Retailers argue their products come "from the kratom plant" and therefore inherit whatever regulatory tolerance kratom itself enjoys. It is the same argument that would let a shop sell 95% pure ethanol as "from grapes".

The wellness marketing frame that got us here

Walk into any US highway service station and you will find the shelf. It sits next to the CBD gummies and the energy shots. The packaging is clean, botanical, sans-serif. The claims are careful: "mood support", "natural energy", "plant-based focus", "for the modern professional".

Reading these labels through a longevity-medicine lens is instructive. A responsible wellness supplement declares its mechanism, its dose, its duration of action and its known contraindications. A 7-OH product declares none of these. It calls itself "wellness" because that word does not have a regulatory definition, and because the word is doing work the product cannot do.

The consumer who buys a 7-OH tablet at 11pm to "wind down" is not, from the receptor's point of view, taking a herbal supplement. They are taking a low-dose opioid. If they take it nightly for six weeks, they will develop tolerance. If they stop, they will experience withdrawal — restless legs, anxiety, sweating, GI distress, insomnia — indistinguishable from mild opioid withdrawal because it is mild opioid withdrawal.

None of the packaging tells them this. That is the story.

The hype deconstruction: what this isn't

Given this is a Signal-9 story, most of the hype deconstruction runs the other way — the story is being under-covered in wellness media because it complicates the "natural is safe" narrative that same media has spent a decade building. But two frames are worth pushing back on:

"The DEA is criminalising kratom." No. The scheduling applies specifically to 7-OH and three analogues above a concentration threshold. Whole-leaf kratom products remain federally legal. The distinction is genuinely important and mainstream kratom industry groups have publicly supported the 7-OH action — because 7-OH products have been eating their market share and creating reputational damage for the broader category.

"This is a MAHA / Trump win over Big Pharma." The New York Times reporting (1 July) documents heavy lobbying by natural-kratom industry players with ties to the Trump administration in favour of the 7-OH ban. That lobbying is real and it shaped the timing. But the underlying pharmacology and the HHS eight-factor analysis are not partisan artefacts. Two things can be true: the political story is grubby, and the scheduling is medically defensible.

Stakeholder landscape

People currently using 7-OH products. Population size is genuinely unknown — no regulated market means no reliable sales data — but industry estimates suggest hundreds of thousands to low millions of regular US consumers. A meaningful subset are physiologically dependent. This is the group the wellness industry created and the treatment system now has to catch.

People using natural kratom for chronic pain or opioid tapering. A quieter cohort with a genuine harm-reduction case. The American Kratom Association estimates 1–2 million regular users. Their use pattern is not what the DEA is targeting, but confusion in the coming months is inevitable. This group needs clearer public communication than they are currently getting.

Convenience-store retailers. A commercially significant category. Trade publication CSP Daily News reported the move on 2 July with an operational focus — pull the products, check state law, expect audits.

The natural kratom industry. Winner in the near term. Losers in the longer term if the public conflates kratom broadly with what 7-OH has been doing.

Clinicians and addiction medicine. A new patient category walks in the door tomorrow, without a diagnostic code that quite fits and without insurance codes that quite pay. Buprenorphine works. Access to buprenorphine is the bottleneck. This is the same access problem the field has been fighting for a decade.

International regulators. Australia (kratom Schedule 9 since 2005), the UK (Psychoactive Substances Act 2016), and much of the EU already prohibit or heavily restrict kratom and its derivatives. Thailand — where the plant is native — legalised kratom in 2021 for pain management and traditional use. The US move on 7-OH does not resolve the global patchwork, but it removes a common industry argument that the US regulatory position on kratom-derivatives was uniquely permissive.

Cross-layer implications

The wellness-supplement / drug boundary is now a defensible target. Every US regulatory action against a "wellness" product from ashwagandha at cardiotoxic doses to tianeptine ("gas station Xanax") to 7-OH has followed the same pattern: legal category ambiguity → aggressive retail expansion → concentration and potency escalation → dependence signal → belated scheduling. The pattern is now visible enough that it is worth naming as a category. Expect the next candidate — likely a novel synthetic cannabinoid or a high-dose kava concentrate — inside 18 months.

The addiction-medicine system will absorb the caseload. Workit Health's launch on 7 July is the first signal. Expect Ophelia, Bicycle Health and Boulder Care to follow within weeks. This is a soft-launch event for the online buprenorphine model, which — despite its clinical strength — remains reimbursement-constrained across most Medicaid systems.

Non-US audiences: the "gas station" retail model is a US-specific vulnerability. Australia, the UK and most EU countries do not permit unregulated supplements to be sold alongside food and fuel. This is one of the quiet structural reasons the US wellness-supplement harm surface is larger than the equivalent in comparable economies. It is worth naming rather than ignoring.

What to do if this affects you or someone in your life

Addressed to the general public. If you are a clinician or harm-reduction worker, most of this will be familiar; sections marked with an asterisk contain the newer material.

If you are currently using 7-OH products regularly (daily or near-daily use for more than 3–4 weeks):

1. Do not stop suddenly. Cold withdrawal from 7-OH is unpleasant and can drive relapse or a switch to more dangerous opioids. It is medically manageable but should be planned.
2. Talk to a buprenorphine-authorised clinician. In the US, any prescriber can now initiate buprenorphine — the X-waiver requirement was removed in 2023. Telehealth options are available in most states. Workit Health, Ophelia, Bicycle Health and Boulder Care all offer online buprenorphine intake within 24–72 hours.
3. If you cannot access buprenorphine immediately, a supervised taper of your current 7-OH product across 2–4 weeks — decreasing dose by roughly 20–25% per week — is a reasonable interim step. This is not medical advice; it is the general contour of what an outpatient plan tends to look like.
4. Withdrawal symptoms to expect: restless legs, anxiety, sweating, GI upset, insomnia, low mood. Onset typically 12–24 hours after last dose, peak at 48–72 hours, largely resolved by day 7–10 for most users. Post-acute symptoms (low motivation, sleep disturbance) can persist for weeks.

If someone you love uses these products:

• The shame frame does not work here and will actively delay treatment. These are people who bought a product marketed as a supplement at a convenience store. Treat this as a medication-management problem, not a moral one.
• The single most useful thing you can do is help them get a buprenorphine appointment. That is the intervention.

If you use kratom leaf products (not 7-OH concentrates) for pain or as an opioid taper:

• The DEA action does not affect you at federal level. State law varies. Six states — Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin — have kratom bans. Some counties and cities restrict it.
• If your use is stable, low-dose and functional, the harm-reduction literature is genuinely unresolved. This is not the same conversation as 7-OH dependence.
• If you find yourself escalating dose or reaching for products that emphasise potency ("extra strength", "extract", "7-hydroxy"), the trajectory you are on is closer to the 7-OH pattern than the traditional-use pattern.

For everyone:

• Read supplement labels for the phrase "7-hydroxymitragynine", "7-OH", "7-hydroxy" or "extract with enhanced 7-hydroxy content". Any of those is the compound now being scheduled.
• The wellness industry's use of the word "natural" is not a safety claim. It is a marketing claim. The 7-OH story is the cleanest recent case study of the difference.

Uncertainty ledger

• Total US 7-OH consumer population is genuinely unknown. All estimates should be read as ranges. A reliable epidemiological picture will emerge from ED admissions and buprenorphine intakes over the next 6–12 months.
• Whether the two-year emergency scheduling becomes permanent depends on DEA and HHS follow-up rulemaking. The current move is time-limited.
• The 7-OH withdrawal syndrome has not been formally characterised in the peer-reviewed literature to the extent traditional opioid withdrawal has. Clinical descriptions from Workit Health and others are converging but the evidence base is early.
• Whether buprenorphine is the optimal treatment for 7-OH dependence, or whether the compound's pharmacology warrants a modified protocol, is an open question. Early clinical practice is applying standard OUD protocols. Data will follow.
• State-level responses — copycat scheduling actions, retail restrictions, penalty structures — will vary and are not yet clear.

The Bottom Line

The wellness industry built a legal opioid, sold it next to the beef jerky, and used the word "natural" to keep the regulators back. It worked for three years. It doesn't work anymore. But the people who are physically dependent right now do not care what shelf the product came off — they need a buprenorphine appointment this week, not a moral lecture next month. If you use these products, or someone you love does, the treatment pathway is well-established and effective. The stigma will lag the pharmacology by a decade. Don't wait for it to catch up.

Sources

• The New York Times (Tier 1) — "Trump Administration Delivers Lucrative Win for Its Kratom Allies", 1 July 2026
• WIRED (Tier 1) — "The DEA Plans to Ban Opioid-Like Kratom Compound 7-OH", 2 July 2026
• CSP Daily News (Tier 2) — "DEA to temporarily schedule 7-OH into the same category as heroin and LSD", 2 July 2026
• US DEA / HHS / FDA official filings and statements, 1–7 July 2026 (Tier 1 — primary regulatory documents)
• Business Insider / Workit Health press announcement (Tier 2) — "Workit Health Expands Online Care to Address Rising Kratom and 7-OH Dependence", 7 July 2026
• WJCT News 89.9 (Tier 2/3) — advocacy interview on emergency ban and calls for permanence, 7 July 2026
• Australian Therapeutic Goods Administration — kratom Schedule 9 listing, 2005 (Tier 1, contextual)
• UK Home Office — Psychoactive Substances Act 2016, kratom coverage (Tier 1, contextual)
• Thailand Narcotics Control Board — kratom decriminalisation, 2021 (Tier 1, contextual)